nach oben

Spektrum der Augenheilkunde

Erschienen in:

01.08.2020 | DFP-Fortbildung

Konjunktivale Malignome

verfasst von: Prof. Dr. Claudia Auw-Hädrich, Thomas Reinhard

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Auszug

Nach der Lektüre dieses Beitrags …

kennen Sie die Epidemiologie und Risikofaktoren der Bindehautmalignome,
wissen Sie, welche (adjuvante) Therapie bei Bindehautmalignomen bzw. ihrer metastasierten Form sinnvoll ist,
können Sie Ihre Patienten bezüglich der Prognose der Bindehautmalignome beraten.

…

Vorheriger Artikel Gamma-Knife-Radiochirurgie in der Ophthalmoonkologie

Nächster Artikel Augenheilkunde

Emmanuel B, Ruder E, Lin S‑W et al (2012) Incidence of squamous-cell carcinoma of the conjunctiva and other eye cancers in the NIH-AARP Diet and Health Study. Ecancermedicalscience 6:254. https://doi.org/10.3332/ecancer.2012.254 CrossRefPubMedPubMedCentral

Sun EC, Fears TR, Goedert JJ (1997) Epidemiology of squamous cell conjunctival cancer. Cancer Epidemiol Biomarkers Prev 6:73–77PubMed

Lee GA, Hirst LW (1992) Incidence of ocular surface epithelial dysplasia in metropolitan Brisbane. A 10-year survey. Arch Ophthalmol 110(1960):525–527CrossRef

Gichuhi S, Sagoo MS, Weiss HA, Burton MJ (2013) Epidemiology of ocular surface squamous neoplasia in Africa. Trop Med Int Health 18:1424–1443. https://doi.org/10.1111/tmi.12203 CrossRefPubMedPubMedCentral

Sjö LD, Ralfkiaer E, Prause JU et al (2008) Increasing incidence of ophthalmic lymphoma in Denmark from 1980 to 2005. Invest Ophthalmol Vis Sci 49:3283–3288. https://doi.org/10.1167/iovs.08-1768 CrossRefPubMed

Yu G‑P, Hu D‑N, McCormick S, Finger PT (2003) Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 135:800–806CrossRef

Tuomaala S, Kivelä T (2003) Conjunctival melanoma: is it increasing in the United States? Am J Ophthalmol 136:1189–1190 (author reply 1190)CrossRef

Grossniklaus HE, Eberhart CG, Kivelä TT (2018) WHO classification of tumours of the eye, 4. Aufl. IARC (International Agency for the Research on Cancer) Publications, Lyon

Parrozzani R, Frizziero L, Trainiti S et al (2017) Topical 1 % 5‑fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study. Br J Ophthalmol 101:1094–1099. https://doi.org/10.1136/bjophthalmol-2016-309219 CrossRefPubMed

10.

Gates AE, Kaplan LD (2002) AIDS malignancies in the era of highly active antiretroviral therapy. Oncology 16:441–451, 456, 459PubMed

11.

Bredow L, Martin G, Reinhard T et al (2009) Recurrent conjunctival papilloma progressing into squamous cell carcinoma with change of HPV-finding during the course. Br J Ophthalmol 93:1437, 1451. https://doi.org/10.1136/bjo.2007.132852 CrossRefPubMed

12.

Auw-Haedrich C, Martin G, Spelsberg H et al (2008) Expression of p16 in conjunctival intraepithelial neoplasia does not correlate with HPV-infection. Open Ophthalmol J 2:48–56. https://doi.org/10.2174/1874364100802010048 CrossRefPubMedPubMedCentral

13.

Eng H‑L, Lin T‑M, Chen S‑Y et al (2002) Failure to detect human papillomavirus DNA in malignant epithelial neoplasms of conjunctiva by polymerase chain reaction. Am J Clin Pathol 117:429–436. https://doi.org/10.1309/RVUP-QMU3-5X6W-3CQ1 CrossRefPubMed

14.

Kallen C, Reinhard T, Schilgen G et al (2003) Atopic keratoconjunctivitis: probably a risk factor for the development of conjuntival carcinoma. Ophthalmologe 100:808–814. https://doi.org/10.1007/s00347-003-0809-z CrossRefPubMed

15.

McKelvie PA, Daniell M, McNab A et al (2002) Squamous cell carcinoma of the conjunctiva: a series of 26 cases. Br J Ophthalmol 86:168–173CrossRef

16.

Wittekind C (2017) TNM: Klassifikation maligner Tumoren, 8. Aufl. Wiley, Weinheim

17.

Siedlecki AN, Tapp S, Tosteson ANA et al (2016) Surgery versus interferon Alpha-2b treatment strategies for ocular surface squamous neoplasia: a literature-based decision analysis. Cornea 35:613–618. https://doi.org/10.1097/ICO.0000000000000766 CrossRefPubMedPubMedCentral

18.

El-Sawy T, Sabichi AL, Myers JN et al (2012) Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol 130:1608–1611. https://doi.org/10.1001/archophthalmol.2012.2515 CrossRefPubMed

19.

Galor A, Karp CL, Oellers P et al (2012) Predictors of ocular surface squamous neoplasia recurrence after excisional surgery. Ophthalmology 119:1974–1981. https://doi.org/10.1016/j.ophtha.2012.04.022 CrossRefPubMedPubMedCentral

20.

Ramberg I, Heegaard S, Prause JU et al (2015) Squamous cell dysplasia and carcinoma of the conjunctiva. A nationwide, retrospective, epidemiological study of Danish patients. Acta Ophthalmol (Copenh) 93:663–666. https://doi.org/10.1111/aos.12743 CrossRef

21.

Tabbara KF, Kersten R, Daouk N, Blodi FC (1988) Metastatic squamous cell carcinoma of the conjunctiva. Ophthalmology 95:318–321CrossRef

22.

Westekemper H, Schallenberg M, Tomaszewski A et al (2011) Malignant epibulbar tumours: new strategies in diagnostics and therapy. Klin Monatsbl Augenheilkd 228:780–792. https://doi.org/10.1055/s-0029-1246068 CrossRefPubMed

23.

Jakobiec FA, Folberg R, Iwamoto T (1989) Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva. Ophthalmology 96:147–166CrossRef

24.

Shields CL, Chien JL, Surakiatchanukul T et al (2017) Conjunctival tumors: review of clinical features, risks, biomarkers, and outcomes--the 2017 J. Donald M. Gass lecture. Asia Pac J Ophthalmol 6:109–120. https://doi.org/10.22608/APO.201710 CrossRef

25.

Damato B, Coupland SE (2008) Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging. Clin Exp Ophthalmol 36:786–795. https://doi.org/10.1111/j.1442-9071.2008.01888.x CrossRefPubMed

26.

Koopmans AE, Ober K, Dubbink HJ et al (2014) Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci 55:6024–6030. https://doi.org/10.1167/iovs.14-14901 CrossRefPubMed

27.

Griewank KG, Westekemper H, Murali R et al (2013) Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res 19:3143–3152. https://doi.org/10.1158/1078-0432.CCR-13-0163 CrossRefPubMed

28.

Pache M, Glatz-Krieger K, Sauter G, Meyer P (2006) Expression of sex hormone receptors and cell cycle proteins in melanocytic lesions of the ocular conjunctiva. Graefes Arch Clin Exp Ophthalmol 244:113–117. https://doi.org/10.1007/s00417-005-0035-2 CrossRefPubMed

29.

Auw-Hädrich C, Reinhard T (2006) Bindehautmelanom. Z Prakt Augenheilkd 27:244–250

30.

Vora GK, Demirci H, Marr B, Mruthyunjaya P (2017) Advances in the management of conjunctival melanoma. Surv Ophthalmol 62:26–42. https://doi.org/10.1016/j.survophthal.2016.06.001 CrossRefPubMed

31.

Kikuchi I, Kase S, Ishijima K, Ishida S (2017) Long-term follow-up of conjunctival melanoma treated with topical interferon alpha-2b eye drops as adjunctive therapy following surgical resection. Graefes Arch Clin Exp Ophthalmol 255:2271–2276. https://doi.org/10.1007/s00417-017-3754-2 CrossRefPubMed

32.

Damato B, Coupland SE (2009) An audit of conjunctival melanoma treatment in Liverpool. Eye 23:801–809. https://doi.org/10.1038/eye.2008.154 CrossRefPubMed

33.

Wuestemeyer H, Sauerwein W, Meller D et al (2006) Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma. Graefes Arch Clin Exp Ophthalmol 244:438–446. https://doi.org/10.1007/s00417-005-0093-5 CrossRefPubMed

34.

Pahlitzsch M, Bertelmann E, Mai C (2014) Conjunctival melanoma and BRAF inhibitor therapy. J Clin Exp Ophthalmol 5:322CrossRef

35.

Shields CL, Kaliki S, Al-Dahmash SA et al (2012) American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes. Ophthal Plast Reconstr Surg 28:313–323. https://doi.org/10.1097/IOP.0b013e3182611670 CrossRefPubMed

36.

Larsen A‑C, Dahl C, Dahmcke CM et al (2016) BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions. Acta Ophthalmol 94:463–470. https://doi.org/10.1111/aos.13007 CrossRefPubMed

37.

Glossmann J‑P, Skoetz N, Starbatty B et al (2018) Conjunctival melanoma : Standard operating procedures in diagnosis, treatment and follow-up care. Ophthalmologe 115:489–498. https://doi.org/10.1007/s00347-018-0664-6 CrossRefPubMed

38.

Coupland SE, Krause L, Delecluse HJ et al (1998) Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Ophthalmology 105:1430–1441. https://doi.org/10.1016/S0161-6420(98)98024-1 CrossRefPubMed

39.

Kirkegaard MM, Coupland SE, Prause JU, Heegaard S (2015) Malignant lymphoma of the conjunctiva. Surv Ophthalmol 60:444–458. https://doi.org/10.1016/j.survophthal.2015.05.001 CrossRefPubMed

40.

Rasmussen PK (2013) Diffuse large B‑cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features. Acta Ophthalmol 5:1–27. https://doi.org/10.1111/aos.12189 (91 Thesis)CrossRef

41.

Kirkegaard MM, Rasmussen PK, Coupland SE et al (2016) Conjunctival lymphoma—an international multicenter retrospective study. Jama Ophthalmol 134:406–414. https://doi.org/10.1001/jamaophthalmol.2015.6122 CrossRefPubMed

42.

Sniegowski MC, Roberts D, Bakhoum M et al (2014) Ocular adnexal lymphoma: validation of American Joint Committee on Cancer seventh edition staging guidelines. Br J Ophthalmol 98:1255–1260. https://doi.org/10.1136/bjophthalmol-2013-304847 CrossRefPubMed

43.

Rath S, Connors JM, Dolman PJ et al (2014) Comparison of American Joint Committee on Cancer TNM-based staging system (7th edition) and Ann Arbor classification for predicting outcome in ocular adnexal lymphoma. Orbit 33:23–28. https://doi.org/10.3109/01676830.2013.842257 CrossRefPubMed

44.

Suesskind D, Ziemssen F, Rohrbach JM (2015) Conjunctival amyloidosis—clinical and histopathologic features. Graefes Arch Clin Exp Ophthalmol 253:1377–1383. https://doi.org/10.1007/s00417-015-2932-3 CrossRefPubMed

45.

Yen MT, Bilyk JR, Wladis EJ et al (2018) Treatments for ocular adnexal lymphoma: a report by the American Academy of Ophthalmology. Ophthalmology 125:127–136. https://doi.org/10.1016/j.ophtha.2017.05.037 CrossRefPubMed

46.

Pinnix CC, Dabaja BS, Milgrom SA et al (2017) Ultra-low-dose radiotherapy for definitive management of ocular adnexal B‑cell lymphoma. Head Neck 39:1095–1100. https://doi.org/10.1002/hed.24717 CrossRefPubMedPubMedCentral

47.

Schmitz N, Nickelsen M, Ziepert M et al (2012) Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B‑cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 13:1250–1259. https://doi.org/10.1016/S1470-2045(12)70481-3 CrossRefPubMed

48.

Geisler CH, Kolstad A, Laurell A et al (2012) Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 158:355–362. https://doi.org/10.1111/j.1365-2141.2012.09174.x CrossRefPubMed

49.

Coupland SE, Heegaard S, Loeffler KU et al (2018) Haematolymphoid tumours of the conjunctiva and caruncle. In: Grossniklaus HE, Eberhart CG, Kivelä TT (Hrsg) WHO classification of tumours of the eye, 4. Aufl. International Agency for Research on Cancer, Lyon, S 40–41

Titel: Konjunktivale Malignome
verfasst von: Prof. Dr. Claudia Auw-Hädrich
Thomas Reinhard
Publikationsdatum: 01.08.2020
Verlag: Springer Vienna
Erschienen in: Spektrum der Augenheilkunde / Ausgabe 4/2020
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI: https://doi.org/10.1007/s00717-020-00450-w

spektrum der augenheilkunde – Publisher’s Report 2019

editorial

Gamma-Knife-Radiochirurgie in der Ophthalmoonkologie

original article

Augenheilkunde

buchbesprechung

Medizinalrat Dr. Hans Sackl 1926–2019

nachruf

Langzeitverlauf nach primärer tiefer Sklerektomie bei Patienten mit niedriger Basisaugendrucklage

original article

Springer Medizin Österreich

Konjunktivale Malignome

Auszug

Weitere Artikel der Ausgabe 4/2020

spektrum der augenheilkunde – Publisher’s Report 2019

Gamma-Knife-Radiochirurgie in der Ophthalmoonkologie

Augenheilkunde

Medizinalrat Dr. Hans Sackl 1926–2019

Langzeitverlauf nach primärer tiefer Sklerektomie bei Patienten mit niedriger Basisaugendrucklage

Springer Medizin Österreich

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

spektrum der augenheilkunde – Publisher’s Report 2019

Gamma-Knife-Radiochirurgie in der Ophthalmoonkologie

Augenheilkunde

Medizinalrat Dr. Hans Sackl 1926–2019

Langzeitverlauf nach primärer tiefer Sklerektomie bei Patienten mit niedriger Basisaugendrucklage